Kintegral Advisory LLC Sells 9,036 Shares of Zoetis Inc. (NYSE:ZTS)

Kintegral Advisory LLC decreased its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 32.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 18,423 shares of the company's stock after selling 9,036 shares during the quarter. Kintegral Advisory LLC's holdings in Zoetis were worth $3,033,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Schroder Investment Management Group raised its position in Zoetis by 2.6% during the 4th quarter. Schroder Investment Management Group now owns 245,726 shares of the company's stock valued at $40,036,000 after purchasing an additional 6,169 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Zoetis by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company's stock valued at $6,739,905,000 after acquiring an additional 120,158 shares in the last quarter. Portside Wealth Group LLC raised its holdings in shares of Zoetis by 24.7% during the first quarter. Portside Wealth Group LLC now owns 33,709 shares of the company's stock valued at $5,550,000 after acquiring an additional 6,672 shares in the last quarter. OFI Invest Asset Management purchased a new stake in Zoetis in the fourth quarter worth $37,298,000. Finally, Sei Investments Co. boosted its holdings in Zoetis by 16.8% in the fourth quarter. Sei Investments Co. now owns 431,899 shares of the company's stock valued at $70,371,000 after acquiring an additional 62,025 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. UBS Group decreased their price objective on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Wall Street Zen upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. Piper Sandler raised their price objective on shares of Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Monday, May 12th. Finally, Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and cut their price objective for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $212.13.

Insider Transactions at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the business's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the sale, the executive vice president directly owned 15,129 shares of the company's stock, valued at approximately $2,571,930. The trade was a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.18% of the company's stock.

Zoetis Trading Up 0.1%

Shares of NYSE ZTS opened at $159.19 on Friday. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $200.33. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.74 and a quick ratio of 1.04. The firm has a 50-day moving average of $161.05 and a 200 day moving average of $162.20. The stock has a market cap of $70.87 billion, a P/E ratio of 28.58, a price-to-earnings-growth ratio of 2.64 and a beta of 0.91.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The business had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. During the same quarter last year, the firm earned $1.38 earnings per share. The business's revenue for the quarter was up 1.4% on a year-over-year basis. As a group, sell-side analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.26%. The ex-dividend date is Friday, July 18th. Zoetis's dividend payout ratio (DPR) is presently 35.91%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.